The global newborn screening market size is estimated to expand at a considerable CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to rising numbers of childbirth, increasing government initiatives for health awareness, and rising incidence of inborn disease in neonates.
Newborn screening is a medical procedure in which physician extract some blood specimen from infant’s heal within 24-48 hours after birth. This screening test is carried out in order to ensure the health of newborn child at a later stage of life. Newborn screening test is performed by various techniques such as blood test involve removal of blood specimen, hearing test which involve extraction of blood specimen through small earpiece, and CCHD screen utilize oximeter on skin of infant. The blood sample is normally submitted to clinical laboratory where medical professional diagnoses and analyse to predict what could be the possible disease condition in the near future.
This test is used to perform for early characterization and diagnosis to prevent possible conditions related to various disorders leading to cause death or physical abnormalities and offer children to live life without any medical intervention. The possibilities of various diseases are detected in newborn screening such as genetic disorders, congenital hypothyroidism, cystic fibrosis, phenylketonuria, congenital adrenal hyperplasia, galactosaemia, and disorder related to circulatory systems. These are key diseases that are expected to occur in future if the test results are found to be positive. The Centers for Disease Control and Prevention (CDC) developed a special plan for newborn screening quality assurance program (NSQAP), which aims to provide precise test results.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing government initiative toward newborn screening tests, rising incidence of inborn disease in infants, and development in technology are projected to boost the market expansion in the upcoming years.
- Rapid growth of the healthcare providers involved in newborn screening test are the major factor spurring the market growth during the forecast period.
- The coronavirus (COVID-19) pandemic is expected to propel the market growth due to rising awareness among people and increasing healthcare expenditure.
- Medical procedure that utilizes blood withdrawal can cause possible infection or bleeding, lack of effective evaluation, and lack of skilled medical professionals & infrastructure in the laboratories are the factors estimated to hinder the market growth.
- Increasing rate of childbirth has resulted to rising demand for newborn screening and rising in the research collaboration among key players is estimated to create lucrative opportunities for market expansion in the coming years.
Scope of the Report
The report on the global newborn screening market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Newborn Screening Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Products (Instruments and Reagents & Assay Kits), Technology (Tandem Mass Spectrometry, Pulse Oximetry, Enzyme Based Assays, DNA Assays, and Electrophoresis), and Tests (Dried Blood Spot Test, Critical Congenital Heart Disease, and Hearing Screen)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Natus Medical, Inc.; Trivitron Healthcare; GE Healthcare; Masimo Corporation; DH Tech. Dev. Pte. Ltd.; Waters Corporation; PerkinElmer, Inc., and Bio-Rad Laboratories, Inc.
|
Global Newborn Screening Market Segment Insights
Reagents & assay kits segment to account for a key share
Based on products, the global newborn screening market is bifurcated into instruments and reagents & assay kits. The reagents & assay kits segment is expected to account for a key share of the market in the coming years owing to the wide adoption of assay kits for several screening process of newborn babies. However, the instruments segment is anticipated to expand at a rapid pace during the forecast period due to wide applicability of mass spectrometer, pulse oximeter, fractionator, and other.
Tandem mass spectrometry is a dominant segment
On the basis of technology, the market is classified into tandem mass spectrometry, pulse oximetry, enzyme-based assays, DNA assays, and electrophoresis. The tandem mass spectroscopy segment is a dominant segment that held a major market share in terms of revenue generation in 2020 due to its capacity to manifest high-speed diagnosis and low price. The segment is expected to hold a major share of the market during the forecast period. However, the pulse oximetry segment is projected to expand at a considerable growth rate in the upcoming years owing to improved qualitative diagnosis. Furthermore, the electrophoresis segment is projected to register strong CAGR during the forecast period owing to its ability to detect infection or health disorder at early stage.
Dried blood spot is expected to grow at a rapid pace
In terms of types, the global newborn screening market is segregated into dried blood spot test, critical congenital heart disease, and hearing screen. The dried blood spot segment is anticipated to represent a major market share with a rapid growth rate during the forecast period due to easy availability of blood collection cards across the globe supported by several government health agencies.
North America is projected to dominate the market
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a major market share in terms of revenue in 2020 and is estimated to register a significant CAGR share during the forecast period due to higher incidence rate of inborn disorder in infants in the region. However, the market in Asia Pacific is expected to grow at significant pace in the upcoming years due to increasing childbirth rate and increasing populace.
Segments
Segments Covered in the Report
The global newborn screening market has been segmented on the basis of
Products
- Instruments
- Reagents & Assay Kits
Technology
- Tandem Mass spectrometry
- Pulse Oximetry
- Enzyme Based Assays
- DNA Assays
- Electrophoresis
Tests
- Dried Blood Spot Test
- Critical congenital heart disease
- Hearing Screen
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Natus Medical, Inc.
- Trivitron Healthcare
- GE Healthcare
- Masimo Corporation
- DH Tech. Dev. Pte. Ltd.
- Waters Corporation
- PerkinElmer, Inc.
- Bio-Rad Laboratories, Inc.
Competitive Landscape
Some of the key contributors in the market are Agilent Technologies, Inc.; Natus Medical, Inc.; Trivitron Healthcare; GE Healthcare; Masimo Corporation; DH Tech. Dev. Pte. Ltd.; Waters Corporation; PerkinElmer, Inc., and Bio-Rad Laboratories, Inc. Many of these key players are actively investing in research & development to develop novel newborn screening technologies to attain business augmentation that can contribute to the market growth. Several of these companies are actively engaged in various market strategies such as product launches, mergers, partnerships, acquisitions, and expansion of production units to enhance their market position and expand their consumer base globally. In September 2013, Agilent Technologies in collaboration with trivitron healthcare developed highly accurate diagnostic method on mass spectroscopy.
Request For Customization
Enquiry Before Buying
Speak With Analyst
